Preclinical and clinical studies showed that PI3K/AKT/mTOR pathway inhibition has a synergistic effect with endocrine therapies, and could reduce tumor progression in HR+ PI3K mutant BCs beyond the first endocrine line of treatment [34,38,39]. Here, MTOR is linked to neoplasm.